ALGS Q3 FY2026 earnings: results, stock reaction and implied move

Reported results

Net loss for the three months ended September 30, 2026 was $21.9 million, or basic and diluted net loss per common share of $(2.09).
Research and development (R&D) expenses for the three months ended September 30, 2026 were $18.9 million.
General and administrative (G&A) expenses for the three months ended September 30, 2026 were $5.9 million.
Cash, cash equivalents and investments totaled $31.1 million as of September 30, 2026.
Revenue from customers for the three months ended September 30, 2026 was $2,830 thousand.

Cash and cash equivalents are expected to provide sufficient funding of planned operations into the first quarter of 2027.
Topline data for both the HBeAg+ and HBeAg- cohorts of the Phase 2 B-SUPREME study are expected in late Q3 2027.

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.